| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CT83 |
| Uniprot No | Q5H943 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-113aa |
| 氨基酸序列 | MNFYLLLASSILCALIVFWKYRRFQRNTGEMSSNSTALALVRPSSSGLINSNTDNNLAVYDLSRDILNNFPHSIARQKRILVNLSMVENKLVELEHTLLSKGFRGASPHRKST |
| 预测分子量 | 14.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于CT83重组蛋白的参考文献示例(请注意，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**: *Expression and Immunogenicity of Recombinant CT83 Protein in Cancer Immunotherapy*
**作者**: Smith J, et al. (2020)
**摘要**: 研究利用大肠杆菌系统表达CT83重组蛋白，通过纯化获得高纯度产物，并验证其在体外和小鼠模型中诱导特异性T细胞免疫反应的能力，为基于CT83的癌症疫苗开发提供依据。
2. **文献名称**: *CT83 Recombinant Protein as a Serological Biomarker for Lung Cancer Detection*
**作者**: Zhang L, et al. (2018)
**摘要**: 评估CT83重组蛋白在肺癌患者血清中的抗体反应，证实其作为非侵入性诊断标志物的潜力，灵敏度和特异性分别达到78%和92%。
3. **文献名称**: *Structural Characterization of CT83 Recombinant Protein by X-ray Crystallography*
**作者**: Patel R, et al. (2021)
**摘要**: 通过晶体学解析CT83重组蛋白的三维结构，揭示其抗原表位特征，为靶向药物设计和表位特异性抗体开发提供结构基础。
4. **文献名称**: *Development of a CT83-based Recombinant Protein Vaccine for Breast Cancer*
**作者**: Lee S, et al. (2019)
**摘要**: 利用杆状病毒-昆虫细胞系统表达CT83重组蛋白，结合佐剂进行动物实验，结果显示疫苗显著抑制肿瘤生长并延长生存期。
---
**说明**：
- CT83(癌症/睾丸抗原83)通常与肿瘤免疫治疗相关，上述摘要围绕重组蛋白的表达、诊断应用、结构研究和疫苗开发展开。
- 实际文献需在PubMed、Web of Science等平台以关键词“CT83 recombinant protein”或“CTAG2”(可能别名)检索确认。
CT83 (also known as CXorf61) is a cancer/testis antigen (CTA) that has garnered significant interest in oncology research due to its tumor-specific expression profile. CTAs like CT83 are typically expressed in germline cells but silenced in most healthy somatic tissues. However, they become reactivated in various malignancies, making them attractive targets for cancer diagnostics and immunotherapy. CT83 is particularly associated with solid tumors, including non-small cell lung cancer (NSCLC), breast cancer, and hepatocellular carcinoma, where its expression correlates with advanced disease stages and poorer prognosis.
The CT83 recombinant protein is produced using genetic engineering techniques, often through the insertion of the CT83 gene into expression vectors (e.g., E. coli or mammalian cell systems) followed by purification processes. This engineered protein retains the immunogenic epitopes of native CT83 while ensuring batch-to-batch consistency and scalability for research or therapeutic applications. Its primary applications include:
1. **Diagnostic development**: Serving as an antigen in serological assays to detect CT83-specific antibodies in patient sera.
2. **Vaccine research**: Being investigated as a component of cancer vaccines to stimulate CT83-directed T-cell responses.
3. **Basic research**: Facilitating studies on CT83's biological role in tumorigenesis, immune evasion, and epigenetic regulation.
Recent studies highlight CT83's potential as a biomarker for minimal residual disease monitoring and its interaction with the MHC class I pathway, which may influence tumor immunogenicity. However, challenges remain in understanding its precise cellular functions and optimizing its therapeutic applications while minimizing off-target effects.
×
